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ABSTRACT
Objective: We aimed to identify the minimum tumor-free margin distance conferring long-
term oncological safety in patients diagnosed with International Federation of Gynecology 
and Obstetrics (FIGO) stage IB/II vulvar squamous cell carcinoma (VSCC).
Methods: This was a retrospective cohort study in patients with stage IB/II VSCC treated at a 
single institution in Turin, Italy. The main aim was to identify the minimum tumor-free margin 
distance that confers oncological safety in early-stage VSCC. Patients were divided in groups 
according to tumor-free histological margin distance to compare survival outcomes. Overall 
survival (OS), disease-specific survival (DSS), and recurrence rate (RR) were estimated by the 
Kaplan-Meier method for the newly proposed and the currently recommended 8 mm margin 
cut-off. Log-rank test was used to compare survival between groups.
Results: One hundred and fourteen patients met the study criteria. Median age was 68 years 
and median follow-up was 80 months. The minimum margin distance that conferred long-
term oncological safety was 5 mm. OS, DSS were significantly lower in the <5 mm group 
when compared with the ≥5 mm group (p=0.002 and p=0.033, respectively) although no 
difference in RR was observed between groups. Analysis at the 8-mm cut-off indicated there 
is no difference in OS, DSS, or RR between groups.
Conclusion: FIGO stage IB/II VSCC patients' prognosis is affected by margin distance. Long-
term survival is significantly reduced in patients with tumor-free margins <5 mm, even in the 
absence of lymph node metastasis. Thus, these patients should be offered further surgical or 
adjuvant treatment.
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INTRODUCTION
Vulvar squamous cell carcinoma (VSCC) is a rare malignancy with an incidence of 1–2 per 
100,000 women-years [1,2] in women younger than age 50 years, rising to as much as 13 per 
100,000 women-years in women older than 85 years [2]. Traditionally, the surgical treatment 
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for early-stage VSCC was a complete resection of the tumor lesion with at least 2 cm tumor-free 
margins [3] with or without unilateral or bilateral inguino-femoral lymphadenectomy, depending 
on tumor size and location [4-6]. However, in the last decade, there have been efforts to limit 
the morbidity and psychological effects of radical surgery while maintaining good oncological 
control. The current consensus is to achieve a surgical margin >1 cm with a histological tumor-
free margin ≥8 mm in early-stage VSCC [3,7-10], although there has been growing criticism on 
the conflicting data available on the role of margin distance on VSCC recurrence and overall 
survival (OS) [11-16]. This lack of consensus is clearly demonstrated in the recommendations of 
German, U.S. and European vulvar cancer treatment guidelines. In Germany, expert consensus 
of the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) and Deutsche 
Krebsgesellschaft (DKG) guidelines recommend a minimum tumor-free margin of 3 mm on 
histological examination [17], whereas in the U.S., the National Comprehensive Cancer Network 
(NCCN) guidelines recommend tumor-free margins of 1–2 cm in early-stage VSCC [18]. Finally, 
the European Society of Gynecological Oncology (ESGO) advises to consider narrow margin in 
aims to preserve key structures such as the clitoris or anus [16].
Most studies in the literature have mixed disease stage cohorts (i.e., positive and 
negative nodal disease combined in a single cohort), mixed treatment approaches (i.e., 
lymphadenectomy vs. sentinel lymph node biopsy or both) or may lack long-term follow-up. 
Thus, they do not provide specific information on the effect of margin distance on long-term 
survival in early-stage, node negative VSCC. In the only published study of early-stage VSCC, 
Woelber et al. [15] found no significant impact of tumor-free margin distance on recurrence 
rate (RR) at the 8-mm margin cut-off, although with a median follow-up of 35.1 months, this 
study does not provide information on the effects of margin distance on long-term survival 
in the stage IB/II VSCC subgroup. Therefore, the main aim of this study was to identify a 
minimum tumor-free margin cut-off that provides long-term oncological safety in early-
stage, node negative VSCC patients.
MATERIALS AND METHODS
This was a retrospective cohort study. Clinical records of patients diagnosed with primary 
invasive, keratinizing VSCC from 1981 to 2014 at St. Anna Hospital, were reviewed. Patients 
with bowenoid or basaloid squamous cell carcinoma on histology were excluded. Patients 
with International Federation of Gynecology and Obstetrics (FIGO) (2009) stages IB/II 
[19], who had a radical total or partial vulvectomy or a wide local excision of the tumor, 
with negative margins, known histological margin distance, bilateral inguino-femoral 
lymphadenectomy with negative lymph nodes were included in the analysis. Patients who 
only had a sentinel lymph node biopsy were excluded from the study. Among the 569 patients 
treated in our clinic in that period, 114 met the study criteria. All 114 patients underwent 
bilateral inguino-femoral lymphadenectomy and were operated by the same surgeon. 
Evaluation of tumor-free margin distance was performed by 2 pathologists on hematoxylin 
and eosin stained slides. The presence of lichen sclerosus as a peri-tumoral lesion was 
recorded. The study was approved by the Institutional Review Board of the Sant'Anna 
Hospital, University of Turin in Italy.
1. Primary and secondary outcomes
The primary aim was to identify the minimum tumor-free margin distance that confers long-
term oncological safety in patients diagnosed with early-stage VSCC (FIGO IB/II), treated with 
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vulvectomy plus bilateral lymphadenectomy. For this, a preliminary analysis was performed 
on tumor-free margin distance and its effect on long-term survival. The secondary outcome 
was to compare OS, disease-specific survival (DSS) and RR at the minimum margin cut-off, 
in order to compare survival outcomes to those observed at the recommended 8 mm margin 
cut-off. For this, the cohort (n=114) was divided into <5 mm and ≥5 mm margins (which 
corresponds to the minimal margin-distance cut-off found in the preliminary analysis) and 
later, the same cohort (n=114) was divided into <8 and ≥8 mm, which corresponds to the 
minimum histologic margin distance recommended in the literature [3,7-10].
2. Topographic classification of vulvar recurrences
The localization of the tumor and local recurrences were recorded. For a precise anatomical 
localization of the lesion, the vulva was divided into 4 areas delimited by an imaginary 
horizontal line passing through the superior border of the hymen (i.e., anterior and posterior 
lesion) and by a vertical line from the clitoris to the anus (i.e., right or left lesion). An ipsi-
regional vulvar recurrence was considered to be a vulvar cancerous lesion that developed on 
the same vulvar area with respect to the location of the primary VSCC. A non ipsi-regional 
vulvar recurrence was considered to be a vulvar cancerous lesion that developed on a different 
vulvar area with respect to the location of the initially treated primary VSCC [17]. All patients' 
records contained a detailed drawing of the tumor's location in relation to the vulvar 
anatomy, while most patients' files also contained a Polaroid photograph of the vulvar tumor 
taken at the time of diagnosis.
3. Statistical analysis
Patients' age, body mass index, tumor size, tumor invasion depth, tumor-free margin 
distance, number of inguino-femoral lymph nodes removed and clinical follow-up data were 
recorded and compared between groups with unpaired t-test or Mann-Whitney test. Time to 
VSCC recurrence and corresponding treatment received was also recorded.
In the preliminary analysis, margin distance was treated as a continuous and categorical 
variable, as previously reported in the literature [15], with aims to identify the minimum 
margin distance that conferred long-term oncological safety in terms of OS. Once the 
minimum margin distance was identified (5 mm, see results section and Supplementary 
Figs. 1-9) and the patient cohort was divided according to margin distance at the 5 mm and 
8 mm cut-off to assess the effect of margin distance on OS, DSS, and RR. OS, DSS, and RR 
were estimated by the Kaplan-Meier method. Log-rank test was used to compare the survival 
curves at the < cut-off and ≥ cut-off. In OS, an event was defined as death by advanced vulvar 
cancer or death by any cause, while in DSS an event was defined as death by vulvar cancer. 
Patients with no events at the time of their last follow-up were considered censored. The 
effect of margin status on patient survival was further evaluated with Fisher's exact test. 
Statistical analysis was performed with GraphPad Prism version 6 (GraphPad Software, La 
Jolla, CA, USA). Differences were significant at p<0.05.
RESULTS
One hundred and fourteen patients met the study criteria. Mean age of VSCC patients at 
diagnosis was 68 years (median 69 years, range 35–89 years). Patients underwent either a 
total radical vulvectomy (n=46) or partial vulvectomy (n=68) plus bilateral inguino-femoral 
lymphadenectomy with triple incisions (n=114), complete removal of inguino-femoral lymph 
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nodes with sparing of the femoral fascia [20]. All patients had negative lymph nodes on 
histopathological examination. None of the patients received adjuvant treatment following 
primary VSCC surgery. Vulvar recurrences were treated surgically, whereas patients who 
developed metastatic disease received adjuvant treatment. Mean length of follow-up was 89 
months (median 80 months, range 5–273 months), whereas 71% of patients in this cohort 
had periodical clinical follow-up documented for at least 90 months.
From the 114 patients analyzed, 46 (40%) developed vulvar recurrences (3 of which developed 
concomitant metastatic disease), 18 died of vulvar cancer, 5 died of other malignancies (1 of 
breast cancer, 2 of ovarian cancer, and 2 of lung cancer) and 7 died of cancer-unrelated causes 
during the follow-up period. Overall, vulvar RR at 2, 5, and 7 years post-surgery was 4%, 13%, 
and 31%, respectively. Ipsi-regional recurrences were recorded in 18 out of 46 patients (39%), 
while non ipsi-regional recurrences were observed in 28 out of 46 patients (61%). Median 
time from surgery to ipsi-regional or non ipsi-regional recurrences was 17 and 59 months, 
respectively. Median time from first recurrence to death by VSCC was 17 months (range 
1–133 months, n=18). Ipsi-regional recurrences were associated with a significantly higher 
disease-specific mortality when compared with non ipsi-regional recurrences (hazard ratio 
[HR]=6.28; 95% confidence interval [CI]=2.04–19.4; p=0.001, log-rank test, Supplementary 
Fig. 1). Further analysis revealed no association between the presence of peri-tumoral lichen 
sclerosus lesions reported within the margin of resection (n=59) and VSCC RR (p=0.44, 
Fisher's exact test).
OS at 2, 5, and 7 years was 95%, 86%, and 78%. DSS was 96%, 90%, and 84% at 2, 5, and 7 
years following surgical treatment of the primary tumor. Median survival of patients that died 
from VSCC was 44 months (range 13–158 months, n=18).
1. Minimum tumor-free margin distance
Preliminary analysis at 8 different tumor-free margin cut-offs (3–10 mm) indicates that 5 mm 
is the minimum margin distance that confers oncological safety in terms of long-term patient 
survival. There is a significant decrease in OS at the 3–5 mm margin cut-offs (Supplementary 
Figs. 2, 3, 4). Furthermore, there is a striking difference in OS at the 5-mm cut-off when 
comparing the <5 mm and ≥5 mm groups (p=0.002, log-rank test, Supplementary Fig. 4). 
No difference in long-term OS was evident at the 6–10 mm margin cut-offs (Supplementary 
Figs. 5, 6, 7, 8, 9).
2. Effect of margin distance in RR and mortality
RR did not differ between groups at the 5-mm margin cut-off (Fig. 1), nor was evident at the 
recommended 8 mm margin cut-off (Fig. 2). The incidence of ipsi-regional recurrence lesions 
was similar between the <5 mm and ≥5 mm margin groups (41% vs. 38%, respectively). 
Although disease-specific mortality was high in patients with <5 mm surgical margins who 
developed ipsi-regional recurrences (4/5 or 80%), formal statistical analysis was not possible 
due to the small the sample size.
OS was significantly lower in the <5 mm group when compared with the ≥5 mm margin group 
(p=0.002; HR=2.92; 95% CI=1.25–6.83, log-rank test). Furthermore, 5-year DSS was 88% 
for the <5 mm margin group and 91% for the ≥5 mm margin group (p=0.033; HR=3.27; 95% 
CI=1.09–9.79, log-rank test, Fig. 3). Differences in OS and DSS were not evident when the 
cohort was divided at the 8-mm margin cut-off (Supplementary Fig. 7 and Fig. 4, respectively).
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Patients with histopathological margins <5 mm, who developed at least one local vulvar 
recurrence had a 7-fold increase in mortality when compared to patients who also developed 
at least one local vulvar recurrence but had histopathological margins ≥5 mm (p=0.018, 
odds ratio [OR]=7.14; 95% CI=1.39–35.1, Fisher's exact test). The increased risk of mortality 
in patients with at least one local vulvar recurrence was not observed between groups 
at the 8 mm margin cut-off (p>0.99, Fisher's exact test). Clinical and pathological data 
comparison between groups at the 5 mm cut-off and 8 mm cut-off can be found in Table 1 
and Supplementary Table 1, respectively.
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Patients at risk
Margins <5 mm 29 21 17 11 9 6 4 2
Margins ≥5 mm 85 71 50 34 26 18 12 3
Time (mo)
p=0.720
0.6
0.4
0.2
0 48 96 144 192 240 288
RR
0.8
1.0
24 72 120 168 216 264
<5 mm (n=29)
≥5 mm (n=85)
Fig. 1. RR in patients with tumor-free surgical margins <5 mm (n=29) or ≥5 mm (n=85), following surgical 
treatment for stage IB/II (FIGO 2009) VSCC. Number of patients at risk is provided at the bottom of the figure. 
Log-rank test was used to compare curves among groups. 
FIGO, International Federation of Gynecology and Obstetrics; RR, recurrence rate; VSCC, vulvar squamous cell 
carcinoma.
Patients at risk
Margins <8 mm 67 52 39 25 19 12 6 2
Margins ≥8 mm 47 40 29 20 16 11 10 3
Time (mo)
p=0.210
0.6
0.4
0.2
0 48 96 144 192 240 288
RR
0.8
1.0
24 72 120 168 216 264
<8 mm (n=67)
≥8 mm (n=47)
Fig. 2. RR in patients with tumor-free surgical margins <8 mm (n=67) or ≥8 mm (n=47), following surgical 
treatment for stage IB/II (FIGO 2009) VSCC. Number of patients at risk is provided at the bottom of the figure. 
Log-rank test was used to compare curves among groups. 
FIGO, International Federation of Gynecology and Obstetrics; RR, recurrence rate; VSCC, vulvar squamous cell 
carcinoma.
DISCUSSION
Surgery is the cornerstone of treatment for primary VSCC [21-24] and for the treatment of 
loco-regional vulvar recurrences [21,23,25], while VSCC prognosis is mainly determined by 
disease stage, lymph node status, age and tumor-related features [21]. Current data in the 
literature regarding a minimum oncologically safe margin distance, are contradictory [21]. In 
the case of early-stage, node-negative VSCC, there is limited knowledge on prognostic factors 
for recurrence and long-term survival. In this study, we show that tumor-free margin distance 
is clinically relevant from a treatment point of view, with a significant effect on prognosis. 
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Patients at risk
Margins <5 mm 29 25 22 16 10 7 6 2
Margins ≥5 mm 85 78 61 48 35 27 20 3
Time (mo)
HR=3.27; 95% CI=1.09–9.79
p=0.033
0.6
0.4
0.2
0 48 96 144 192 240 288
DS
S
0.8
1.0
24 72 120 168 216 264
<5 mm (n=29)
≥5 mm (n=85)
Fig. 3. DSS in patients with tumor-free surgical margins <5 mm (n=29) or ≥5 mm (n=85), following surgical 
treatment for stage IB/II (FIGO 2009) VSCC. Number of patients at risk is provided at the bottom of the figure. 
Log-rank test was used to compare survival curves among groups. 
CI, confidence interval; DSS, disease-specific survival; FIGO, International Federation of Gynecology and 
Obstetrics; HR, hazard ratio; VSCC, vulvar squamous cell carcinoma.
Patients at risk
Margins <8 mm 67 60 48 38 24 17 13 2
Margins ≥8 mm 47 43 34 26 20 16 13 3
Time (mo)
p=0.170
0.6
0.4
0.2
0 48 96 144 192 240 288
DS
S
0.8
1.0
24 72 120 168 216 264
<8 mm (n=67)
≥8 mm (n=47)
Fig. 4. DSS in patients with tumor-free surgical margins <8 mm (n=67) or ≥8 mm (n=47), following surgical 
treatment for stage IB/II (FIGO 2009) VSCC. Number of patients at risk is provided at the bottom of the figure. 
Log-rank test was used to compare survival curves among groups. 
DSS, disease-specific survival; FIGO, International Federation of Gynecology and Obstetrics; VSCC, vulvar 
squamous cell carcinoma.
The data indicate that a histological margin of 5 mm is the minimum distance required to 
ensure oncological safety and long-term survival in patients with lymph node-negative, 
FIGO stage IB/II VSCC. Our data also indicate that margin distance has no significant impact 
on RR, in agreement with previous reports in the literature [11,13,15,26]. However, there is 
clear evidence that margin distance <5 mm has a significant impact on long-term survival, 
increasing VSCC mortality by a 3-fold, when compared with the ≥5 mm margin group. The 
median survival of patients that developed recurrences and died from vulvar cancer was 44 
months, which illustrates the importance of long-term follow-up in VSCC patients.
It is commonly thought that node-negative VSCC has a good prognosis, with 5-year survival 
rates ranging from 70%–96% [24,25,27]. In our study of 114 FIGO (2009) [19] stage IB/II 
VSCC patients, 5-year OS was 86% for the whole cohort, in agreement with the literature. 
However, survival changed dramatically when the sample was divided into groups according 
to tumor-free minimum margin distance <5 mm or ≥5 mm. Thus, the data indicate that 
surgical treatment of early-stage, node negative VSCC is not always curative and highlights 
the importance of surgical margins where approximately 1 in 4 patients with histological 
margins <5 mm will eventually die from VSCC.
Time from treatment to recurrence and the prognosis of a vulvar recurrences is influenced 
by the location of the local vulvar recurrence and not by the presence of lichen sclerosus 
within the surgical margin. Classification of recurrences was a difficult task, as there is no 
current consensus in the literature with regards to the definition of local VSCC recurrence 
or a ‘de novo’ tumor when considering: 1) the time elapsed from surgical treatment and 2) 
the location of the new lesion (i.e., adjacent to surgical scar vs. remote lesion vs. skin bridge 
lesion) [21]. Maggino et al. [28] defined a recurrence as a malignant lesion that develops at 
least 6 months following VSCC treatment with curative intent, while Preti et al. [29] defined 
it as a malignant lesion that develops 1 month following VSCC treatment. Most authors 
agree the majority of recurrences develop by 2 years following surgery while recurrences that 
develop after 2 years following primary treatment could be defined as ‘de novo’ tumors [3,25].
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Table 1. Clinical and pathological patient data
Clinical data Total (n=114) Tumor-free margins p-value
< 5 mm (n=29) ≥ 5 mm (n=85)
Age (yr) 68 (35–89) 72 (39–85) 68 (35–89) 0.61*
FIGO 2009
Stage IB 104 (90) 26 (87) 78 (92) -
Stage II 11 (10) 4 (13) 7 (8) -
Tumor location
Midline 42 (37) 14 (48) 28 (33) -
Lateral 72 (63) 15 (52) 57 (77)
Tumor focality
Unifocal 102 (89) 26 (90) 76 (89) -
Multifocal 12 (11) 3 (10) 9 (11)
Vulvar treatment
Partial vulvectomy 68 (60) 20 (69) 48 (56) -
Total vulvectomy 46 (40) 9 (31) 37 (44)
Tumor diameter (mm) 18 (5–60) 18 (7–38) 18 (5–60) 0.74*
Depth of Invasion (mm) 4 (2–20) 5 (2–20) 4 (2–12) 0.18†
No. Lymph nodes removed‡ 18 (7–33) 18 (9–29) 18 (7–33) 0.65†
Time to first recurrence§ (mo) 40 (3–142) 45 (6–135) 40 (3–142) 0.85*
Values are presented as number (%) or median (range).
FIGO, International Federation of Gynecology and Obstetrics.
*Unpaired t-test; †Mann-Whitney test; ‡Refers to the number of lymph nodes resected bilaterally; §Refers to a vulvar cancerous lesion that developed following 
surgical treatment of the primary tumor.
In our cohort, recurrence patterns differed significantly according to the location of the 
lesion with respects to the primary VSCC. Patients who present with ipsi-regional vulvar 
recurrences tend to develop earlier and more aggressive lesions when compared with the non 
ipsi-regional recurrence group. This observation was previously described by Rouzier et al. 
[30] in a cohort of 215 VSCC patients, although the study included different criteria of loco-
regional distance from primary VSCC site, patients with mix stages, positive lymph nodes 
and positive margins.
The lack of difference in RR between margin groups at the 5-mm margin cut-off results 
puzzling in the face of such significant effect in survival. A possible explanation is that 
patients with smaller margin distances develop more aggressive recurrences. The notion of a 
‘more aggressive’ recurrence affecting the <5 mm margin group is supported by our findings, 
as patients in the <5 mm margin group who developed a recurrence were 7 times more likely 
to die from VSCC when compared with patients who developed local recurrences in the ≥5 
mm margin group. This is perhaps associated to the peri-tumoral stromal inflammation 
left in situ following the surgical removal of the tumor, which in time may contribute to 
the malignant progression of the remaining tissue [31] and to the development of local and 
metastatic disease [32].
To the best of our knowledge, this is the first report on the impact of margin distance on 
long-term survival in early-stage, node-negative VSCC. Although retrospective in nature, this 
study presents a homogenous patient sample, with similar VSCC prognoses and long-term 
clinical surveillance; a single surgeon performing all procedures in a single-center with a 
systematic and standardized staging of the groin [20] (i.e., total, bilateral lymphadenectomy) 
with histological confirmation of a negative node status. Thus, we believe this study provides 
robust evidence of the effect of margin distance on the long-term survival of patients with 
lymph node-negative, FIGO stage IB/II VSCC.
In conclusion, long-term patient survival in early-stage, lymph node negative VSCC is 
significantly affected by tumor-free margin distance at the 5-mm cut-off. Patients treated 
for early-stage VSCC with margins <5 mm have a significantly higher mortality than patients 
with larger tumor-free margin distance and should therefore be offered further surgical 
or adjuvant treatment. Future prospective studies are needed to identify optimal adjuvant 
treatments and to assess their effect on long-term survival in early-stage VSCC.
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Clinical and pathological data comparison between groups at the 8 mm margin cut-off
Click here to view
Supplementary Fig. 1
Disease-specific survival according to the location of the vulvar recurrence.
Click here to view
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Supplementary Fig. 2
Overall survival at the 3 mm margin cut-off.
Click here to view
Supplementary Fig. 3
Overall survival at the 4 mm margin cut-off.
Click here to view
Supplementary Fig. 4
Overall survival at the 5 mm margin cut-off.
Click here to view
Supplementary Fig. 5
Overall survival at the 6 mm margin cut-off.
Click here to view
Supplementary Fig. 6
Overall survival at the 7 mm margin cut-off.
Click here to view
Supplementary Fig. 7
Overall survival at the 8 mm margin cut-off.
Click here to view
Supplementary Fig. 8
Overall survival at the 9 mm margin cut-off.
Click here to view
Supplementary Fig. 9
Overall survival at the 10 mm margin cut-off.
Click here to view
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